PARTNERING

Vascarta is open to business and scientific partnering opportunities of various kinds.  While we have seen remarkable health benefits in animal models when delivering curcumin transdermally, Vascarta’s patented transdermal delivery technology can do much more in collaboration with partners, including:

1. Delivering a pharmaceutical or wellness company’s poorly orally bioavailable molecules
   • Using existing or new molecules
   • Enhancing patent protection
2. Combining a pharmaceutical or wellness company’s poorly orally bioavailable existing or new molecules with potent botanicals like curcumin, quercetin, and/or Fisetin
3. Enhancing bioactivity and reducing side effects
   • Enhancing patent production
   • Conducting pre-clinical and clinical research on indications of interest to a partner
     1. 1. On Vascarta’s current transdermal formulation containing curcumin, which already has shown benefits for pain, inflammation, endothelial dysfunction, hypertension, Alzheimer’s/anti-aging, blood stabilization, and more.
        2. On Vascarta transdermal formulation variants containing curcumin, quercetin, or Fisetin, alone or in combination
        3. On a potential partner’s existing or new molecules singly or in combination with potent botanicals like curcumin, quercetin, or Fisetin.
4. Providing Vascarta transdermal formulation(s) to academic collaborators wanting to conduct new scientific research

We are willing to discuss licensing or acquisition opportunities such as listed above or other opportunities of interest to a potential licensor or acquirer.  Please contact Vascarta CEO Dr. Richard Prince at rprince@vascarta.com.